{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:25:05Z","timestamp":1769095505308,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00120-020-01274-x","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T12:03:45Z","timestamp":1595246625000},"page":"963-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Botulinumtoxin bei \u00fcberaktiver Blase","Botulinum toxin for overactive bladder"],"prefix":"10.1007","volume":"59","author":[{"given":"B. K.","family":"Ziegelm\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"issue":"10","key":"1274_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/j.1464-410X.2008.07598.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne\u00a0KS, Matza\u00a0LS, Kopp\u00a0ZS, Thompson\u00a0C, Henry\u00a0D, Irwin\u00a0DE et\u00a0al (2008) Examining lower urinary tract symptom constellations using cluster analysis. BJU Int 101(10):1267\u20131273","journal-title":"BJU Int"},{"issue":"4","key":"1274_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","volume":"190","author":"VW Nitti","year":"2013","unstructured":"Nitti\u00a0VW, Rosenberg\u00a0S, Mitcheson\u00a0DH, He\u00a0W, Fakhoury\u00a0A, Martin\u00a0NE (2013) Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J\u00a0Urol 190(4):1320\u20131327","journal-title":"J Urol"},{"issue":"1","key":"1274_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen\u00a0BT, de Ridder\u00a0D, Freeman\u00a0RM, Swift\u00a0SE, Berghmans\u00a0B, Lee\u00a0J et\u00a0al (2010) An international urogynecological association (IUGA)\/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4\u201320","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"1274_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1067\/mob.2002.125704","volume":"187","author":"P Abrams","year":"2002","unstructured":"Abrams\u00a0P, Cardozo\u00a0L, Fall\u00a0M, Griffiths\u00a0D, Rosier\u00a0P, Ulmsten\u00a0U et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Am J Obstet Gynecol 187(1):116\u2013126","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1274_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1124\/mol.104.009449","volume":"68","author":"EB Berry","year":"2005","unstructured":"Berry\u00a0EB, Keelan\u00a0JA, Helliwell\u00a0RJ, Gilmour\u00a0RS, Mitchell\u00a0MD (2005) Nanomolar and micromolar effects of 15-deoxy-delta 12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B. Mol Pharmacol 68(1):169\u2013178","journal-title":"Mol Pharmacol"},{"issue":"5","key":"1274_CR6","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.juro.2011.01.003","volume":"185","author":"YH Jura","year":"2011","unstructured":"Jura\u00a0YH, Townsend\u00a0MK, Curhan\u00a0GC, Resnick\u00a0NM, Grodstein\u00a0F (2011) Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J\u00a0Urol 185(5):1775\u20131780","journal-title":"J Urol"},{"issue":"7","key":"1274_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/nau.20179","volume":"24","author":"ET Bird","year":"2005","unstructured":"Bird\u00a0ET, Parker\u00a0BD, Kim\u00a0HS, Coffield\u00a0KS (2005) Caffeine ingestion and lower urinary tract symptoms in healthy volunteers. Neurourol Urodyn 24(7):611\u2013615","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1274_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa0806375","volume":"360","author":"LL Subak","year":"2009","unstructured":"Subak\u00a0LL, Wing\u00a0R, West\u00a0DS, Franklin\u00a0F, Vittinghoff\u00a0E, Creasman\u00a0JM et\u00a0al (2009) Weight loss to treat urinary incontinence in overweight and obese women. N\u00a0Engl J Med 360(5):481\u2013490","journal-title":"N Engl J Med"},{"issue":"14","key":"1274_CR9","doi-asserted-by":"publisher","first-page":"142301","DOI":"10.1103\/PhysRevLett.107.142301","volume":"107","author":"A Adare","year":"2011","unstructured":"Adare\u00a0A, Afanasiev\u00a0S, Aidala\u00a0C, Ajitanand\u00a0NN, Akiba\u00a0Y, Al-Bataineh\u00a0H et al (2011) Cold nuclear matter effects on J\/psi yields as a\u00a0function of rapidity and nuclear geometry in d+A collisions at sqrt[s(NN)]=200 GeV. Phys Rev Lett 107(14):142301","journal-title":"Phys Rev Lett"},{"issue":"3","key":"1274_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple\u00a0CR, Khullar\u00a0V, Gabriel\u00a0Z, Muston\u00a0D, Bitoun\u00a0CE, Weinstein\u00a0D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a\u00a0systematic review and meta-analysis. Eur Urol 54(3):543\u2013562","journal-title":"Eur Urol"},{"issue":"9","key":"1274_CR11","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner\u00a0JS, Nichol\u00a0MB, Rovner\u00a0ES, Jumadilova\u00a0Z, Alvir\u00a0J, Hussein\u00a0M et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105(9):1276\u20131282","journal-title":"BJU Int"},{"issue":"6","key":"1274_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","volume":"203","author":"SA Kaplan","year":"2020","unstructured":"Kaplan\u00a0SA, Herschorn\u00a0S, McVary\u00a0KT, Staskin\u00a0D, Chapple\u00a0C, Foley\u00a0S et al (2020) Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS). J\u00a0Urol 203(6):1163\u20131171. https:\/\/doi.org\/10.1097\/JU.0000000000000738","journal-title":"J Urol"},{"issue":"4","key":"1274_CR13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"S Herschorn","year":"2017","unstructured":"Herschorn\u00a0S, Chapple\u00a0CR, Abrams\u00a0P, Arlandis\u00a0S, Mitcheson\u00a0D, Lee\u00a0KS et\u00a0al (2017) Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 120(4):562\u2013575","journal-title":"BJU Int"},{"key":"1274_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-019-04070-0","author":"B Bodner-Adler","year":"2019","unstructured":"Bodner-Adler\u00a0B, Alarab\u00a0M, Ruiz-Zapata\u00a0AM, Latthe\u00a0P (2019) Effectiveness of hormones in postmenopausal pelvic floor dysfunction-international urogynecological association research and development-committee opinion. Int Urogynecol\u00a0J. https:\/\/doi.org\/10.1007\/s00192-019-04070-0","journal-title":"Int Urogynecol J"},{"issue":"3","key":"1274_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamainternmed.2019.6398","volume":"180","author":"KL Burgio","year":"2020","unstructured":"Burgio\u00a0KL, Kraus\u00a0SR, Johnson\u00a0TM 2nd, Markland\u00a0AD, Vaughan\u00a0CP, Li\u00a0P et\u00a0al (2020) Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med 180(3):411\u2013419. https:\/\/doi.org\/10.1001\/jamainternmed.2019.6398","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1274_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","volume":"196","author":"VW Nitti","year":"2016","unstructured":"Nitti\u00a0VW, Ginsberg\u00a0D, Sievert\u00a0KD, Sussman\u00a0D, Radomski\u00a0S, Sand\u00a0P et al (2016) Durable efficacy and safety of long-term onabotulinumtoxin A treatment in patients with overactive bladder syndrome: final results of a\u00a03.5-year study. J\u00a0Urol 196(3):791\u2013800","journal-title":"J Urol"},{"key":"1274_CR17","unstructured":"Nitti V et\u00a0al (2015) Vorgestellt beim Kongress AUA 2015, 15.\u201319. Mai, New Orleans, Vortrag"},{"key":"1274_CR18","unstructured":"De Ridder D (2015) Vorgestellt beim Kongress EAU 2015, 20.\u201324. M\u00e4rz 2015, Poster\u00a0149"},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","volume":"135","author":"M Abrar","year":"2020","unstructured":"Abrar\u00a0M, Stroman\u00a0L, Malde\u00a0S, Solomon\u00a0E, Sahai\u00a0A (2020) Predictors of poor response and adverse events following botulinum toxin\u2011A for refractory idiopathic overactive bladder. Urology 135:32\u201337","journal-title":"Urology"},{"issue":"1","key":"1274_CR20","doi-asserted-by":"publisher","first-page":"e0147137","DOI":"10.1371\/journal.pone.0147137","volume":"11","author":"SM Hsiao","year":"2016","unstructured":"Hsiao\u00a0SM, Lin\u00a0HH, Kuo\u00a0HC (2016) Factors associated with therapeutic efficacy of Intravesical onabotulinumtoxin A injection for overactive bladder syndrome. PLoS ONE 11(1):e147137","journal-title":"PLoS ONE"},{"issue":"20","key":"1274_CR21","first-page":"2573","volume":"285","author":"Centers for Disease Control and Prevention","year":"2001","unstructured":"Centers for Disease Control and Prevention (2001) Severe malnutrition among young children\u2014Georgia, January 1997 - June 1999. JAMA 285(20):2573\u20132574","journal-title":"JAMA"},{"issue":"1","key":"1274_CR22","doi-asserted-by":"publisher","first-page":"012304","DOI":"10.1103\/PhysRevLett.96.012304","volume":"96","author":"SS Adler","year":"2006","unstructured":"Adler\u00a0SS, Afanasiev\u00a0S, Aidala\u00a0C, Ajitanand\u00a0NN, Akiba\u00a0Y, Al-Jamel\u00a0A et al (2006) J\/psi production and nuclear effects for d + Au and p + p collisions at square root of S(NN) = 200 GeV. Phys Rev Lett 96(1):12304","journal-title":"Phys Rev Lett"},{"issue":"6","key":"1274_CR23","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/j.juro.2008.08.030","volume":"180","author":"WM White","year":"2008","unstructured":"White\u00a0WM, Pickens\u00a0RB, Doggweiler\u00a0R, Klein\u00a0FA (2008) Short-term efficacy of botulinum toxin a\u00a0for refractory overactive bladder in the elderly population. J\u00a0Urol 180(6):2522\u20132526","journal-title":"J Urol"},{"issue":"8","key":"1274_CR24","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/nau.21132","volume":"30","author":"HC Kuo","year":"2011","unstructured":"Kuo\u00a0HC (2011) Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity. Neurourol Urodyn 30(8):1497\u20131502","journal-title":"Neurourol Urodyn"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-020-01274-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T23:11:07Z","timestamp":1626736267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-020-01274-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01274-x","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"20 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>R.\u00a0M.\u00a0Bauer<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Beratung und Vortr\u00e4ge: Allergan Pharma \u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Beratung und Vortr\u00e4ge: Allergan Pharma \u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin, Urologische Klinik, LMU M\u00fcnchen | Mitgliedschaften: Arbeitskreis Funktionelle Urologie der DGU, Leitlinienkommission Harninkontinenz. <b>B.\u00a0K.\u00a0Ziegelm\u00fcller<\/b>: A.\u00a0Finanzielle Interessen: B.\u00a0K. Ziegelm\u00fcller gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Fach\u00e4rztin Urologie, Funktionsober\u00e4rztin, Urologische Klinik und Poliklinik, Klinikum der Universit\u00e4t M\u00fcnchen, Campus Gro\u00dfhadern. <b>A.\u00a0Sommer<\/b>: A.\u00a0Finanzielle Interessen: A.\u00a0Sommer gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Urologische Klinik und Poliklinik, LMU, Klinikum M\u00fcnchen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}